Dr. Christopher Shen serves as the Executive Director (US) of Singapore-Stanford Biodesign and is also a Consulting Associate Professor of Medicine at Stanford University.

Dr. Shen is also the Managing Director of Vertex Healthcare - part of a global venture fund network under the auspices of Vertex Venture Holdings, a member of Temasek Holdings. Dr. Shen has over 15 years of healthcare investing experience. Prior to joining Vertex, Chris led numerous medtech and biopharma investments at New Enterprise Associates and Essex Woodlands. He worked with seven companies that have since gone public or been successfully acquired, worth over US$1.5 billion in value. He has nine patents issued and several pending in the fields of interventional neuroradiology and interventional cardiology. Previously, Dr. Shen worked in operating roles at Guidant and Pfizer.

Academic Appointments

  • Consulting Associate Professor, Surgery

Administrative Appointments

  • Executive Director, Singapore Stanford Biodesign (2010 - Present)

Boards, Advisory Committees, Professional Organizations

  • Board Member, Kona Medical (2014 - Present)
  • Board Member, Ivantis (2015 - Present)
  • Board Member, Moximed (2014 - Present)

Professional Education

  • MD, Stanford University, School of Medicine
  • MBA, Stanford University, Graduate School of Business
  • MS, Stanford University, Biomechanical Engineering
  • BS, Stanford University, Biological Science

Research & Scholarship

Current Research and Scholarly Interests

Healthcare innovation. Global medical technology assessment/needs finding. Value-driven innovation. Asia-pacific region. Medical technology development, financing, operations, regulatory, reimbursement.